Skip to main content
    • Aa
    • Aa


  • Luis Almenar (a1), Beatriz Díaz (a2), Aurelio Quesada (a3), Carlos Crespo (a4), Belén Martí (a5), Stuart Mealing (a6), Cecilia Linde (a7) and Claude Daubert (a8)...

Objectives: The aim of the study was to combine clinical results from the European Cohort of the REVERSE study and costs associated with the addition of cardiac resynchronization therapy (CRT) to optimal medical therapy (OMT) in patients with mild symptomatic (NYHA I-II) or asymptomatic left ventricular dysfunction and markers of cardiac dyssynchrony in Spain.

Methods: A Markov model was developed with CRT + OMT (CRT-ON) versus OMT only (CRT-OFF) based on a retrospective cost-effectiveness analysis. Raw data was derived from literature and expert opinion, reflecting clinical and economic consequences of patient's management in Spain. Time horizon was 10 years. Both costs (euro 2010) and effects were discounted at 3 percent per annum.

Results: CRT-ON showed higher total costs than CRT-OFF; however, CRT reduced the length of hospitalization in ICU by 94 percent (0.006 versus 0.091 days) and general ward in by 34 percent (0.705 versus 1.076 days). Surviving CRT-ON patients (88.2 percent versus 77.5 percent) remained in better functional class longer, and they achieved an improvement of 0.9 life years (LYGs) and 0.77 years quality-adjusted life years (QALYs). CRT-ON proved to be cost-effective after 6 years, except for the 7th year due to battery depletion. At 10 years, the results were €18,431 per LYG and €21,500 per QALY gained. Probabilistic sensitivity analysis showed CRT-ON was cost-effective in 75.4 percent of the cases at 10 years.

Conclusions: The use of CRT added to OMT represents an efficient use of resources in patients suffering from heart failure in NYHA functional classes I and II.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2. JR Banegas , F Rodríguez-Artalejo , P. Guallar-Castillón [Epidemiological situation of heart failure in Spain]. Rev Esp Cardiol. 2006;6 (Suppl C):49.

5. FM Gomez-Soto , JL Andrey , AA García-Egido , et al.Incidence and mortality of heart failure: A community-based study. Int J Cardiol. 2011;151:4045.

6. D Callejo , M Guerra , A Hernández-Madrid , JA. Blasco Economic assessment of cardiac resynchronization therapy. Rev Esp Cardiol. 2010;63:12351243.

7. MJ Calvert , N Freemantle , G Yao , et al.Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005;26:26812688.

10. AJ Moss , W Jackson , DS Cannom , H Klein , MW Brown , MADIT-CRT trial investigators. Cardiac-resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361:13291338.

11. C Linde , S Mealing , N Hawkins , et al.Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J. 2011;32:16311639.

12. M Fox , S Mealing , R Anderson , et al.The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess. 2007;11:1168, iii-iv, ix-248.

16. JA Sacristán , J Oliva , J Del Llano , L Prieto , JL. Pinto What is an efficient health technology in Spain? Gac Sanit. 2002;16:334343.

17. AM Feldman , G de Lissovoy , MR Bristow , et al.Cost effectiveness of cardiac resynchronisation therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:23112321.

19. MG St John Sutton , T Plappert , WT Abraham , et al.Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:19851990.

20. SL Higgins , JD Hummel , IK Niazi , et al.Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:14541459.

21. C Alonso , P Ritter , C Leclercq , et al.Effects of cardiac resynchronization therapy on heart rate variability in patients with chronic systolic heart failure and intraventricular conduction delay. Am J Cardiol. 2003;91:11441147.

22. G Yao , N Freemantle , MJ Calvert , et al.The long term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28:4251.

23. R Muñoz , J Martínez-Ferrer , J Delgado , et al.[Can cardiac resynchronization therapy added to optimize pharmacological treatment make up in patients with heart failure in Spain?]. PharmacoEconomics Sp Res Art. 2010;7:1325.

24. AS Tang , GA Wells , M Talajic , et al.Resynchronization-defibrillation for ambulatory heart failure trial investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:23852395.

25. MJ Calvert , N Freemantle , JG. Cleland Cardiac resynchronisation therapy is cost effective. Rev Esp Cardiol. 2010;63:12301231.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary Materials

Almenar et al. supplementary material
Supplementary figure 1

 Word (51 KB)
51 KB


Full text views

Total number of HTML views: 3
Total number of PDF views: 14 *
Loading metrics...

Abstract views

Total abstract views: 116 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st September 2017. This data will be updated every 24 hours.